DSM BioSolutions, DSM’s microbial fermentation CMO business unit and PolyTherics Limited an innovator in precision engineering of proteins, today announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG IFN alpha-2a. Continue Reading
The South-Eastern Sydney Illawarra Health Service claims that the risk of contracting blood borne serious viral infections like HIV and Hepatitis are low among patients who had an endoscopy done at a private Warrawong clinic. This clinic came under into the spotlight after investigations started to detect the cause of illness in nine persons who underwent endoscopy. The facility is at Cowper Street, Warrawong run by Dr Zakaria Lakhany and is presently closed. Continue Reading
According to the Australian Nurses Federation (ANF) there are more than 18,000 reports of accidental needle stick injuries to nurses caused by syringes or other sharp items in Australia each year. This increases their risk of contracting deadly blood borne diseases like HIV/AIDS, hepatitis B and C etc. The authorities believe that these figures although alarming are not reflective of the true figures with many nurses choosing to keep their exposure under wraps. Continue Reading
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments. Continue Reading
Unilife Corporation today announced that it has signed an exclusive five-year agreement with Stason Pharmaceuticals Inc, a U.S.-based pharmaceutical company, to market the Unitract™ 1mL safety syringe in Japan, China and Taiwan. Stason’s Taiwan-based strategic alliance affiliate, Standard Chem. and Pharm. Co., LTD, will act as the primary distributor of the product within these designated territories. Continue Reading
Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott’s early- and mid-stage pharmaceutical pipeline. Continue Reading
InterMune, Inc. announced today that the U.S. Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. Continue Reading
NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities. Continue Reading
Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported. Continue Reading
Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain. Continue Reading
